Implantica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Implantica hat ein Gesamteigenkapital von €106.8M und eine Gesamtverschuldung von €0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €111.0M bzw. €4.2M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

€0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€69.34m
Eigenkapital	€106.78m
Gesamtverbindlichkeiten	€4.18m
Gesamtvermögen	€110.96m

Jüngste Berichte zur Finanzlage

Recent updates

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Jul 26

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Mar 06

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

Aug 19

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

May 05

We're Not Very Worried About Implantica's (STO:IMP A SDB) Cash Burn Rate

Jan 14

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Sep 26

Implantica (STO:IMP A SDB) Is In A Strong Position To Grow Its Business

Jan 08

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IMP A SDBDie kurzfristigen Aktiva des Unternehmens (€71.8M) übersteigen seine kurzfristigen Passiva (€3.2M).

Langfristige Verbindlichkeiten: IMP A SDBDie kurzfristigen Vermögenswerte des Unternehmens (€71.8M) übersteigen seine langfristigen Verbindlichkeiten (€976.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IMP A SDB ist schuldenfrei.

Schulden abbauen: IMP A SDB hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 14.3% betrug.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: IMP A SDB auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: IMP A SDB verfügt über eine ausreichende Liquiditätsreserve für 1.6 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 22% pro Jahr abnimmt.

Implantica Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

We're Not Very Worried About Implantica's (STO:IMP A SDB) Cash Burn Rate

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Recent updates

Consensus revenue estimates decrease by 33%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG to Report Q4, 2024 Results on Feb 14, 2025

Implantica AG (publ.) Submits FDA PMA Application Clinical Module 2 for RefluxStop for U.S. Market Approval

Implantica AG to Report Q3, 2024 Results on Nov 15, 2024

Implantica Ag (Publ.) Announces Highly Successful 2024 American Foregut Society Meeting Where Refluxstop Received Remarkable Pre- Launch Market Feedback

Implantica AG announces finalization of remarkable 5-year pivotal CE mark study results and gears up for the Module 2 submission of PMA application to FDA for RefluxStop

Implantica AG Announces Excellent Data from an Independent Study of 158 RefluxStop Patients from Two Centers in Germany - Presented at the AUGIS Meeting in UK

Implantica Announces Demise of Board Member Prof. Dr. Klaus Neftel

Consensus revenue estimates decrease by 17%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG Announces Refluxstop Pivotal 4-Year Study Results Published in the Prestigious Journal Surgical Endoscopy

Implantica Announces Continuing Progress in Modular PMA Application to FDA for Refluxstop

Implantica Announces New Health-economics Data Publication Showing RefluxStop's Superior Cost-Effectiveness for the Swiss Healthcare System

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Implantica Submits U.S. FDA Premarket Approval (PMA) Application for RefluxStop® (first module)

Implantica Completes Human Factors Validation Study for RefluxStop as Part of the US FDA Premarket Approval Process

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Implantica AG, Annual General Meeting, May 22, 2024

Implantica Ag Announces the First RefluxStop Procedures Completed At MIC Hospital in Berlin

New minor risk - Share price stability

Chief Corporate Affairs Officer recently bought kr1.2m worth of stock

Consensus revenue estimates increase by 27%

Consensus revenue estimates fall by 27%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG (publ.)'s RefluxStop Offers for the First Time in the NHS in UK

Insufficient new directors

Implantica AG to Report Q4, 2023 Results on Feb 20, 2024

Implantica AG to Report Q2, 2023 Results on Aug 24, 2023

New minor risk - Share price stability

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Consensus revenue estimates decrease by 21%, EPS upgraded

Implantica AG Announces RefluxStop Results Were Presented At the DDW Conference in Chicago

Implantica AG to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Consensus revenue estimates decrease by 35%, EPS upgraded

Full year 2022 earnings released: €0.30 loss per share (vs €0.055 loss in FY 2021)

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Implantica AG to Report Q4, 2022 Results on Feb 17, 2023

Implantica AG to Report Q1, 2022 Results on May 11, 2022

We Think Implantica (STO:IMP A SDB) Can Easily Afford To Drive Business Growth

High number of new and inexperienced directors

Implantica AG, Annual General Meeting, May 10, 2022

Full year 2021 earnings: EPS misses analyst expectations

Implantica Ag Announces Launch of Refluxstop™ in Uk

Consensus revenue estimates increase by 13%

Implantica AG Announces Filing of Comprehensive eHealth Patent Applications for Its Platform Technology

Full year 2021 earnings: EPS exceeds analyst expectations

Implantica AG to Report Q4, 2021 Results on Feb 18, 2022

Consensus forecasts updated

Implantica AG Appoints Paul Meadas as Chief Operating Officer

We're Not Very Worried About Implantica's (STO:IMP A SDB) Cash Burn Rate

High number of new and inexperienced directors

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Implantica (STO:IMP A SDB) Will Use Its Cash Wisely

Vice-Chairman of the Board recently sold kr14m worth of stock

Second quarter 2021 earnings released: €0.04 loss per share (vs €0.10 loss in 2Q 2020)

Implantica Achieves Regulatory Authorisation for RefluxStop™ in New Zealand

Implantica AG (publ) Makes Headway in Italy and Spain with Its Medical Device RefluxStop™

Implantica Advances in Sweden with its Medical Device Refluxstop™

Revenue behind estimates

Implantica AG to Report Q4, 2020 Results on Feb 25, 2021

Implantica AG (publ)'s RefluxStop™ Makes Strides in the UK